{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:43:56Z","timestamp":1786218236139,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001343","name":"University of Pretoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030570"],"award-info":[{"award-number":["INV-030570"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226137\/Z\/22\/Z"],"award-info":[{"award-number":["226137\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jinf.2026.106676","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:44:24Z","timestamp":1767804264000},"page":"106676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease"],"prefix":"10.1016","volume":"92","author":[{"given":"Rofhiwa","family":"Nesamari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-967X","authenticated-orcid":false,"given":"Dexter T.","family":"Chiveto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanusha","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Kgagudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomcebo","family":"Shusha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Manamela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-4472","authenticated-orcid":false,"given":"Helen C.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1756","authenticated-orcid":false,"given":"Mieke A.","family":"van der Mescht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-1755","authenticated-orcid":false,"given":"Nevilene","family":"Slingers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-1402","authenticated-orcid":false,"given":"Lee-Ann","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-7212","authenticated-orcid":false,"given":"Khanyisile","family":"Tshabalala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ueckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishen","family":"Seocharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarylee","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandeka","family":"Moyo-Gwete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-9430","authenticated-orcid":false,"given":"Fareed","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-4028","authenticated-orcid":false,"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-922X","authenticated-orcid":false,"given":"Theresa M.","family":"Rossouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-024-00972-3","article-title":"Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections","volume":"9","author":"Alirezaylavasani","year":"2024","journal-title":"npj Vaccin"},{"issue":"2","key":"10.1016\/j.jinf.2026.106676_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41423-023-01087-w","article-title":"The immune response to SARS-CoV-2 in people with HIV","volume":"21","author":"H\u00f6ft","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jinf.2026.106676_bib3","doi-asserted-by":"crossref","first-page":"1231276","DOI":"10.3389\/fimmu.2023.1231276","article-title":"Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination","volume":"14","author":"Motsoeneng","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jinf.2026.106676_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/QAI.0000000000003378","article-title":"COVID-19 severity in people with HIV compared with those without HIV","volume":"95","author":"Nguyen","year":"2024","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"8","key":"10.1016\/j.jinf.2026.106676_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad400","article-title":"Risk factors for SARS-CoV-2 infection and severe outcomes among people with human immunodeficiency virus: cohort study","volume":"10","author":"Hanna","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106676_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/QAD.0000000000003597","article-title":"COVID-19 in people with HIV in the Netherlands","volume":"37","author":"Wit","year":"2023","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45520-6","article-title":"Co-infection dynamics of COVID-19 and HIV\/AIDS","volume":"13","author":"Batu","year":"2023","journal-title":"Sci Rep"},{"issue":"16","key":"10.1016\/j.jinf.2026.106676_bib8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/00002030-199816000-00006","article-title":"Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study","volume":"12","author":"Bisset","year":"1998","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.jinf.2026.106676_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e31804d685b","article-title":"CD4 cell counts of 800 cells\/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells\/mm3 or greater","volume":"45","author":"Gras","year":"2007","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"3","key":"10.1016\/j.jinf.2026.106676_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.jinf.2026.106676_bib11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/hiv.13515","article-title":"COVID-19 hospitalization outcomes in adults by HIV status; a nation-wide register-based study","volume":"24","author":"M\u00f6ller","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2026.106676_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15934","article-title":"Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States","volume":"5","author":"Coburn","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib13","doi-asserted-by":"crossref","first-page":"E144","DOI":"10.1093\/cid\/ciac077","article-title":"Prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at high viral loads among hospitalized immunocompromised persons living with human immunodeficiency virus (HIV), South Africa","volume":"75","author":"Meiring","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106676_bib14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3390\/microorganisms12112149","article-title":"T-cell phenotypes and systemic cytokine profiles of people living with HIV admitted to hospital with COVID-19","volume":"12","author":"van der Mescht","year":"2024","journal-title":"Microorganisms"},{"issue":"6","key":"10.1016\/j.jinf.2026.106676_bib15","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jinf.2026.106676_bib16","unstructured":"National Health Laboratory Service. Latest confirmed cases of COVID-19 in South Africa; 2022 [Internet] [cited 2025 Nov 18]. Available from: \u3008https:\/\/web.archive.org\/web\/20251118104709\/https:\/\/www.nhls.ac.za\/latest-confirmed-cases-of-covid-19-in-south-africa-29-july-2022\/\u3009."},{"key":"10.1016\/j.jinf.2026.106676_bib17","doi-asserted-by":"crossref","unstructured":"Hussey H, Vreede H, Davies M-A, Heekes A, Kalk E, Hardie D, et al. Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa. medRxiv [preprint]; 2022:2022.12.01.22282927\u20132022.12.01. DOI:10.1101\/2022.12.01.22282927.","DOI":"10.1101\/2022.12.01.22282927"},{"issue":"14","key":"10.1016\/j.jinf.2026.106676_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and Covid-19 severity with omicron variant in South Africa","volume":"386","author":"Madhi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jinf.2026.106676_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00780-25","article-title":"Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2","volume":"19","author":"Joseph","year":"2025","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib20","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1038\/s41467-021-26137-7","article-title":"Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV","volume":"12","author":"Alrubayyi","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib21","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1093\/cid\/ciab1008","article-title":"Immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Ad26.CoV2.S vaccination in people living with human immunodeficiency virus (HIV)","volume":"75","author":"Khan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib22","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/s41467-022-30163-4","article-title":"Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host","volume":"13","author":"Sonnleitner","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12879-024-09631-3","article-title":"The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody","volume":"24","author":"Maruyama","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12981-020-00301-3","article-title":"Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4+ T cell count","volume":"17","author":"Menghua","year":"2020","journal-title":"AIDS Res Ther"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib25","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1093\/cid\/ciab758","article-title":"Similar antibody responses against severe acute respiratory syndrome coronavirus 2 in individuals living without and with human immunodeficiency virus on antiretroviral therapy during the first South African infection wave","volume":"75","author":"Snyman","year":"2021","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","article-title":"Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy","volume":"7","author":"Brumme","year":"2022","journal-title":"npj Vaccin"},{"issue":"4","key":"10.1016\/j.jinf.2026.106676_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002703","article-title":"Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants","volume":"4","author":"Riou","year":"2024","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.jinf.2026.106676_bib28","doi-asserted-by":"crossref","first-page":"1554409","DOI":"10.3389\/fimmu.2025.1554409","article-title":"Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105862","article-title":"Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles","volume":"26","author":"Touizer","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib30","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1038\/s41467-022-32263-7","article-title":"Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV","volume":"13","author":"Vergori","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jinf.2026.106676_bib31","first-page":"2023","article-title":"Humoral responses elicited by SARS-CoV-2 mRNA vaccine in people living with HIV","volume":"15","author":"Marchitto","year":"2004","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.jinf.2026.106676_bib32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/infdis\/jiac229","article-title":"People with human immunodeficiency virus receiving suppressive antiretroviral therapy show typical antibody durability after dual coronavirus disease 2019 vaccination and strong third dose responses","volume":"227","author":"Lapointe","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106676_bib33","doi-asserted-by":"crossref","first-page":"1136029","DOI":"10.3389\/fimmu.2023.1136029","article-title":"mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in na\u00efve and COVID-19-recovered individuals","volume":"14","author":"Lozano-Rodr\u00edguez","year":"2023","journal-title":"Front Immunol"},{"issue":"770","key":"10.1016\/j.jinf.2026.106676_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp8920","article-title":"SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity","volume":"16","author":"Lasrado","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jinf.2026.106676_bib35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2147\/IDR.S353127","article-title":"Safety and immunogenicity of inactivated COVID-19 vaccines among people living with HIV in China","volume":"15","author":"Han","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"11","key":"10.1016\/j.jinf.2026.106676_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.cmi.2025.06.007","article-title":"Humoral and cellular immune responses in people living with HIV following successive COVID-19 vaccine booster doses","volume":"31","author":"Casado","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.jinf.2026.106676_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/vaccines13050480","article-title":"Antibody response against SARS-CoV-2 spike protein in people with HIV after COVID-19 vaccination","volume":"13","author":"Mu\u00f1oz-G\u00f3mez","year":"2025","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.jinf.2026.106676_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac579","article-title":"A systematic review of COVID-19 vaccine antibody responses in people with HIV","volume":"9","author":"Chun","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12981-022-00459-y","article-title":"Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals","volume":"19","author":"Zou","year":"2022","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jinf.2026.106676_bib40","doi-asserted-by":"crossref","first-page":"1275843","DOI":"10.3389\/fmed.2023.1275843","article-title":"Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2023","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.jinf.2026.106676_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01155-23","article-title":"Robust vaccine-induced as well as hybrid B- and T-cell immunity across SARS-CoV-2 vaccine platforms in people with HIV","volume":"11","author":"Verburgh","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jinf.2026.106676_bib42","doi-asserted-by":"crossref","first-page":"78374","DOI":"10.7554\/eLife.78374","article-title":"Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition","volume":"11","author":"Nkosi","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.jinf.2026.106676_bib43","article-title":"Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41541-021-00414-4","article-title":"SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses","volume":"6","author":"Carmen","year":"2021","journal-title":"npj Vaccin"},{"issue":"3","key":"10.1016\/j.jinf.2026.106676_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87499","article-title":"Polyfunctional and IFN- \u03b3 monofunctional human CD4+ T cell populations are molecularly distinct","volume":"2","author":"Burel","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jinf.2026.106676_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016921","article-title":"A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses","volume":"6","author":"Rosa","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jinf.2026.106676_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201253","article-title":"Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves","volume":"13","author":"Thakur","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/srep36355","article-title":"Adenovirally-induced polyfunctional T cells do not necessarily recognize the infected target: lessons from a phase I trial of the AERAS-402 vaccine","volume":"6","author":"Nyendak","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jinf.2026.106676_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41541-023-00731-w","article-title":"Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN(\u00ae) induced immunity in COVID-19 exposed Indians","volume":"8","author":"Rakshit","year":"2023","journal-title":"NPJ Vaccin"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-022-01300-9","article-title":"Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"17","key":"10.1016\/j.jinf.2026.106676_bib52","doi-asserted-by":"crossref","first-page":"e161045","DOI":"10.1172\/jci.insight.161045","article-title":"Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people","volume":"7","author":"Vitall\u00e9","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib53","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jinf.2026.106676_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2022.01.028","article-title":"Lower probability of persistence of total anti-SARS-CoV-2 antibodies after COVID-19 among people living with HIV","volume":"28","author":"Mac\u00edas","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jinf.2026.106676_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-47106-8","article-title":"COVID-19 vaccine uptake among people with HIV: identifying characteristics associated with vaccine hesitancy","volume":"13","author":"Boschung","year":"2023","journal-title":"Sci Rep"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:26:51Z","timestamp":1786217211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0163445326000010"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106676","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106676"}}